Bayer said explore bid $40 billion seed company Monsanto

Bayer said to explore bid for $40 billion seed company Monsanto

4:35 AM, 16th May 2016
Bayer said to explore bid for $40 billion seed company Monsanto
Monsanto is displayed on a screen where the stock is traded on the floor of the New York Stock Exchange (NYSE) in New York City, US. © Reuters

NEW YORK, US: Bayer AG is exploring a potential bid for US competitor Monsanto Company in a deal that would create the world’s largest supplier of seeds and farm chemicals, according to people familiar with the matter.

The German firm has held preliminary discussions internally and with advisers about buying Monsanto, which has a market value of about $43 billion, said the people, who asked not to be named because the deliberations are private.

Bayer, which is valued at about €79 billion ($90 billion), has discussed how to finance a deal including potential asset sales. No final decision has been made and the Leverkusen-based company could decide against a bid or pursue other transactions with Monsanto, including joint ventures or asset sales, the people said.

Representatives for Bayer and Monsanto declined to comment.

Putting the world’s largest seed maker together with the German company that invented aspirin would bring together brands such as Roundup, Monsanto’s blockbuster herbicide and Sivanto, a new Bayer insecticide lethal to aphids and whiteflies but not to bees, as well as seeds for crops ranging from corn to sugar cane.

Regulatory Scrutiny

Such a deal would face regulatory scrutiny amid an unprecedented wave of consolidation in the crop-chemicals industry.

In crop chemicals, competition authorities are investigating the $130 billion merger between Dow Chemical Co and DuPont Co, while national security officials in the US are weighing China National Chemical Corp’s bid to acquire Syngenta AG of Switzerland for $43 billion.

A Monsanto-Bayer combination isn’t likely to raise significant antitrust hurdles because there’s little overlap in the companies’ products, according to analysts and legal experts.

"From the antitrust side, I don’t think there’ll be many issues," said Lutz Krafft, a senior adviser at consulting firm ChemAdvice GmbH who once worked at Bayer.

Previous Talks

Monsanto rose 8.4 percent to close at $97.92 after news about Bayer’s interest and a report from StreetInsider before that BASF SE is working with advisers to explore a takeover offer. The gain was the largest since August. Bayer shares fell 4.9 percent to €95.15 in Frankfurt, the biggest decline since December.

Monsanto has explored possible deals with Bayer as well as German competitor BASF, people familiar with the matter said in March. Bayer and Monsanto have discussed a number of options from a full combination to the German firm selling all or part of its crop sciences business, as well as joint ventures, the people said at the time. When Bayer raised the idea of a full takeover of Monsanto in March, the US firm said it was not interested in selling, and it sees itself as more of an acquirer, two of the people said.

If Bayer goes ahead with a bid, it would raise pressure on BASF to consider an offer, the people said. A spokeswoman for Bayer declined to comment on potential deals.

Farm Income

Monsanto is grappling with a global slump in agricultural commodities after its offer to buy Syngenta for about $46.2 billion was spurned last year. Sales in the quarter ending in February declined 13 percent from a year earlier to $4.53 billion. Corn and soybean prices fell in the last three calendar years, cutting net farm income in the US and hurting demand for everything from tractors to weed killer.

A deal with Bayer would help the company reduce its reliance on the agriculture industry, while Monsanto would strengthen Bayer’s seed business, one of the company’s priorities.

For Bayer, the talks come as the company is transitioning to new leadership. Strategy head Werner Baumann took over from CEO Marijn Dekkers this month. Dekkers reshaped Bayer, increasing its focus on life sciences by buying Merck & Co’s over-the-counter medicines business and divesting a stake in its plastics unit.

Bayer’s market value has almost doubled since Dekkers took the helm at the end of 2010 as the 152-year-old company sold more prescription drugs for eyes and hearts and added consumer brands like Claritin.

© Bloomberg News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Dow Corning opens new building solutions centre in New Delhi, India

MIDLAND, US: Dow Corning Corporation has opened its first building solutions center, Sahayog in New Delhi, expanding its operations in India. Dedicat ...

Read more
BASF opens new superconductors pilot plant in Germany

RHEINBACH, GERMANY: Deutsche Nanoschicht GmbH, a wholly owned subsidiary of BASF New Business GmbH has opened its new pilot plant for the manufacture ...

Read more
TerraVia changes ticker symbol to ‘TVIA’

SAN FRANCISCO, US: TerraVia (formally Solazyme Inc) said that it will officially begin trading on the NASDAQ global select market under the new tradin ...

Read more
Asahi Glass to expand vinyl chloride monomer capacity in Indonesia

TOKYO, JAPAN: Asahi Glass Company Ltd (AGC) said that it is further increasing the production capacity of vinyl chloride monomer (VCM) at PT Asahimas ...

Read more
Archroma unveils cotton poplin colour atlas for new shades

REINACH, SWITZERLAND: Archroma’s colour management service business has launched a cotton poplin colour atlas, a colour library created to easil ...

Read more
Technip bags Woodside’s engineering services contract

PARIS, FRANCE: Technip SA has been awarded an engineering services contract by Woodside Petroleum Limited to provide multi-disciplinary engineering se ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X